Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer-Reference-Cited by-同舟云学术

Combination of Radiation Therapy and Short-Term Androgen Blockade With Abiraterone Acetate Plus Prednisone for Men With High- and Intermediate-Risk Localized Prostate Cancer

Published:2021-04 Issue:5 Volume:109 Page:1271-1278
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Koontz Bridget F.,Hoffman Karen E.,Halabi Susan,Healy Patrick,Anand Monika,George Daniel J.,Harrison Michael R.,Zhang Tian,Berry William R.,Corn Paul G.,Lee W. Robert,Armstrong Andrew J.

Funder

Janssen Scientific Affairs

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference29 articles.

1. Patterns of prostate cancer treatment by clinical stage and age;Meltzer;Am J Public Health,2001

2. Quality of life in prostate cancer patients taking androgen deprivation therapy;Dacal;J Am Geriatr Soc,2006

3. Abiraterone inhibits 3beta-hydroxysteroid dehydrogenase: a rationale for increasing drug exposure in castration-resistant prostate cancer;Li;Clin Cancer Res,2012

4. Abiraterone and increased survival in metastatic prostate cancer;de Bono;N Engl J Med,2011

5. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911);Bolla;Lancet,2012

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Combination of Abiraterone Acetate, Prostate Bed Radiotherapy, and Luteinizing Hormone-releasing Hormone Agonists in Biochemically Relapsing Patients After Prostatectomy (CARLHA): A Phase 2 Clinical Trial;European Urology Oncology;2024-05

2. Updated 5-year results for short course abiraterone acetate and LHRH agonist for unfavorable intermediate and favorable high-risk prostate cancer;Prostate Cancer and Prostatic Diseases;2024-02-22

3. Radiotherapy in prostatic cancer;Revisiones en Cáncer;2024

4. Novel Approaches in the Systemic Management of High-Risk Prostate Cancer;Clinical Genitourinary Cancer;2023-12

5. An overview of hormonal directed pharmacotherapy for the treatment of prostate cancer;Expert Opinion on Pharmacotherapy;2023-08-07